Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.

Journal: Urology practice
PMID: 39509585

Abstract

INTRODUCTION: No consensus exists on performance standards for evaluation of generative artificial intelligence (AI) to generate medical responses. The purpose of this study was the assessment of Chat Generative Pre-trained Transformer (ChatGPT) to address medical questions in prostate cancer.

Authors

  • Arnulf Stenzl
    Department of Urology, University Hospital of Tübingen, Tübingen, Germany.
  • Andrew J Armstrong
    Duke Cancer Institute Center for Prostate and Urologic Cancer, Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC.
  • Eamonn Rogers
    Department of Urology, University College Hospital, Galway, Ireland.
  • Dany Habr
    Pfizer Oncology, Pfizer Inc, New York, New York.
  • Jochen Walz
    Institut Paoli-Calmettes, Service de chirurgie urologique, Marseille, France.
  • Martin Gleave
    The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
  • Andrea Sboner
    Institute for Precision Medicine.
  • Jennifer Ghith
    Pfizer Oncology, Pfizer Inc, New York, New York.
  • Lucile Serfass
    Pfizer Oncology, Paris, France.
  • Kristine W Schuler
    Pfizer Oncology, Pfizer Inc, New York, New York.
  • Sam Garas
    Pfizer Oncology, Pfizer Inc, New York, New York.
  • Dheepa Chari
    Pfizer Oncology, Pfizer Inc, New York, New York.
  • Ken Truman
    Insights & Connections, MedThink Inc, Cary, North Carolina.
  • Cora N Sternberg
    Department of Medicine, Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. Electronic address: cns9006@med.cornell.edu.

Keywords

External Resources

Popular Topics
Recent Journals